Rociletinib could become a “game changer” in treating EGFR-mutation driven lung tumors which have become treatment resistant
by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical outcomes.